Non-Arrhenius Protein Aggregation
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 3
Abstract
Protein aggregation presents one of the key challenges in the development of protein biotherapeutics. It affects not only product quality but also potentially impacts safety, as protein aggregates have been shown to be linked with cytotoxicity and patient immunogenicity. Therefore, investigations of protein aggregation remain a major focus in pharmaceutical companies and academic institutions. Due to the complexity of the aggregation process and temperature-dependent conformational stability, temperature-induced protein aggregation is often non-Arrhenius over even relatively small temperature windows relevant for product development, and this makes low-temperature extrapolation difficult based simply on accelerated stability studies at high temperatures. This review discusses the non-Arrhenius nature of the temperature dependence of protein aggregation, explores possible causes, and considers inherent hurdles for accurately extrapolating aggregation rates from conventional industrial approaches for selecting accelerated conditions and from conventional or more advanced methods of analyzing the resulting rate data.
Authors and Affiliations
Wei Wang, Christopher J. Roberts
Keywords
Related Articles
- EP ID EP681144
- DOI 10.1208/s12248-013-9485-3
- Views 87
- Downloads 0
Kinetics of hallmark biochemical changes in paclitaxel-induced apoptosis
Apoptosis is associated with cascades of biochemical changes, including caspase activation, cleavage of poly-ADP-ribose polymerase (PARP), and fragmentation of genomic DNA. Knowledge of the kinetics of these changes in d...
Modeling Testosterone Circadian Rhythm in Hypogonadal Males: Effect of Age and Circannual Variations
The objective of this study was to characterize the baseline circadian rhythm of testosterone levels in hypogonadal men. A total of 859 baseline profiles of testosterone from hypogonadal men were included in this analysi...
Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches
Physiologically based pharmacokinetic (PBPK) models are built using differential equations to describe the physiology/anatomy of different biological systems. Readily available in vitro and in vivo preclinical data can b...
Vesicular monoamine transporter 2: Role as a novel target for drug development
In the central nervous, system, vesicular monoamine transporter 2 (VMAT2) is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles for storage and subsequent exocytotic release. Pharmacological...
On some “disadvantages” of the population approach
In a seminal article on population pharmacokinetic modeling, researchers demonstrated how means and variances of pharmacokinetic parameters for a patient population could be inferred from sparse data collected under cond...